
## **Daniel Scherman**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7758769/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Persistent luminescence nanoparticles functionalized by polymers bearing phosphonic acid anchors: synthesis, characterization, and <i>in vivo</i> behaviour. Nanoscale, 2022, 14, 1386-1394.	5.6	11
2	Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells using the Sleeping Beauty Transposon System. Journal of Visualized Experiments, 2021, , .	0.3	2
3	PLGA Based Nanospheres as a Potent Macrophage-Specific Drug Delivery System. Nanomaterials, 2021, 11, 749.	4.1	27
4	Viscous Core Liposomes Increase siRNA Encapsulation and Provides Gene Inhibition When Slightly Positively Charged. Pharmaceutics, 2021, 13, 479.	4.5	8
5	Cationic lipid nanoparticle production by microfluidization for siRNA delivery. International Journal of Pharmaceutics, 2021, 605, 120772.	5.2	7
6	Degradation of ZnGa <sub>2</sub> O <sub>4</sub> :Cr <sup>3+</sup> luminescent nanoparticles in lysosomal-like medium. Nanoscale, 2020, 12, 1967-1974.	5.6	23
7	Coating Persistent Luminescence Nanoparticles With Hydrophilic Polymers for in vivo Imaging. Frontiers in Chemistry, 2020, 8, 584114.	3.6	2
8	Drug repositioning for rare diseases: Knowledge-based success stories. Therapie, 2020, 75, 161-167.	1.0	41
9	Drug repurposing in rare diseases: Myths and reality. Therapie, 2020, 75, 157-160.	1.0	36
10	Polymer Nanomedicines with Ph-Sensitive Release of Dexamethasone for the Localized Treatment of Inflammation. Pharmaceutics, 2020, 12, 700.	4.5	6
11	Reduced Heterochromatin Formation on the pFAR4 Miniplasmid Allows Sustained Transgene Expression in the Mouse Liver. Molecular Therapy - Nucleic Acids, 2020, 21, 28-36.	5.1	5
12	Kinetic and structural characterization of therapeutic albumin chemical functionalization using complementary mass spectrometry techniques. Journal of Pharmaceutical and Biomedical Analysis, 2020, 185, 113242.	2.8	4
13	Neurotrophin gene augmentation by electrotransfer to improve cochlear implant hearing outcomes. Hearing Research, 2019, 380, 137-149.	2.0	20
14	Hemocompatibility investigation and improvement of near-infrared persistent luminescent nanoparticle ZnGa <sub>2</sub> O <sub>4</sub> :Cr <sup>3+</sup> by surface PEGylation. Journal of Materials Chemistry B, 2019, 7, 3796-3803.	5.8	51
15	Small-scale GMP production of plasmid DNA using a simplified and fully disposable production method. Journal of Biotechnology, 2019, 306, 100007.	3.8	12
16	Efficient episomal gene transfer to human hepatic cells using the pFAR4–S/MAR vector. Molecular Biology Reports, 2019, 46, 3203-3211.	2.3	8
17	Europium labeled lactosylated albumin as a model workflow for the development of biotherapeutics. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 18, 21-30.	3.3	2
18	Microbubbles for Nucleic Acid Delivery in Liver Using Mild Sonoporation. Methods in Molecular Biology, 2019, 1943, 377-387.	0.9	7

_			-	
D/	A NEE	E1	SC	RMAN
Ur	-	LL	JC	

#	Article	IF	CITATIONS
19	Preclinical Evaluation of a Cell-Based Gene Therapy Using the Sleeping Beauty Transposon System in Choroidal Neovascularization. Molecular Therapy - Methods and Clinical Development, 2019, 15, 403-417.	4.1	13
20	Imaging and therapeutic applications of persistent luminescence nanomaterials. Advanced Drug Delivery Reviews, 2019, 138, 193-210.	13.7	220
21	GENOME ENGINEERING AND GENOME EDITING USING CRISPR/CAS9–RNA-GUIDED NUCLEASE. , 2019, , 115-13	30.	0
22	GENETIC THERAPY OF MUSCLE DISEASES: DUCHENNE MUSCULAR DYSTROPHY. , 2019, , 503-526.		0
23	BASIC DEFINITIONS AND GENERAL PRINCIPLES. , 2019, , 7-15.		Ο
24	ADOPTIVE IMMUNOTHERAPY AND CAR-T CELLS: A REVOLUTIONARY CELL/GENE THERAPY TO TREAT CANCER. , 2019, , 377-390.		0
25	ELECTROTRANSFER/ELECTROPORATION FOR NON-VIRAL NUCLEIC ACID DELIVERY. , 2019, , 281-301.		0
26	The Antibiotic-free pFAR4 Vector Paired with the Sleeping Beauty Transposon System Mediates Efficient Transgene Delivery in Human Cells. Molecular Therapy - Nucleic Acids, 2018, 11, 57-67.	5.1	11
27	Improved molecular platform for the gene therapy of rare diseases by liver protein secretion. European Journal of Medical Genetics, 2018, 61, 723-728.	1.3	9
28	Nanohybrids with Magnetic and Persistent Luminescence Properties for Cell Labeling, Tracking, In Vivo Realâ€Time Imaging, and Magnetic Vectorization. Small, 2018, 14, e1800020.	10.0	38
29	Assessment of the targeting specificity of a fluorescent albumin conceived as a preclinical agent of the liver function. Nanoscale, 2018, 10, 21151-21160.	5.6	7
30	Genetic pharmacology: progresses in siRNA delivery and therapeutic applications. Gene Therapy, 2017, 24, 151-156.	4.5	45
31	Engineering of PEDF-Expressing Primary Pigment Epithelial Cells by the SB Transposon System Delivered by pFAR4 Plasmids. Molecular Therapy - Nucleic Acids, 2017, 6, 302-314.	5.1	24
32	The absorption enhancer sodium deoxycholate promotes high gene transfer in skeletal muscles. International Journal of Pharmaceutics, 2017, 523, 291-299.	5.2	3
33	Toll-like receptor 2 promiscuity is responsible for the immunostimulatory activity of nucleic acid nanocarriers. Journal of Controlled Release, 2017, 247, 182-193.	9.9	13
34	Cyanine derivative as a suitable marker for thermosensitive in situ gelling delivery systems: In vitro and in vivo validation of a sustained buccal drug delivery. International Journal of Pharmaceutics, 2017, 534, 128-135.	5.2	31
35	Long-Term PEDF Release in Rat Iris and Retinal Epithelial Cells after Sleeping Beauty Transposon-Mediated Gene Delivery. Molecular Therapy - Nucleic Acids, 2017, 9, 1-11.	5.1	14
36	Cationic microbubbles and antibiotic-free miniplasmid for sustained ultrasound–mediated transgene expression in liver. Journal of Controlled Release, 2017, 262, 170-181.	9.9	35

#	Article	IF	CITATIONS
37	Assessment of dually labelled PEGylated liposomes transplacental passage and placental penetration using a combination of two ex-vivo human models: the dually perfused placenta and the suspended villous explants. International Journal of Pharmaceutics, 2017, 532, 729-737.	5.2	23
38	Persistent luminescence induced by near infra-red photostimulation in chromium-doped zinc gallate for inÂvivo optical imaging. Optical Materials, 2017, 63, 51-58.	3.6	41
39	Anionic pH-Sensitive Lipoplexes. Methods in Molecular Biology, 2017, 1522, 227-236.	0.9	1
40	Liposome Biodistribution via Europium Complexes. Methods in Molecular Biology, 2017, 1522, 145-154.	0.9	1
41	Chemically engineered persistent luminescence nanoprobes for bioimaging. Theranostics, 2016, 6, 2488-2523.	10.0	165
42	Synthesis and cytotoxicity evaluation of aryl triazolic derivatives and their hydroxymethine homologues against B16 melanoma cell line. European Journal of Medicinal Chemistry, 2016, 122, 436-441.	5.5	16
43	Characterization of Positively Charged Lipid Shell Microbubbles with Tunable Resistive Pulse Sensing (TRPS) Method: A Technical Note. Ultrasound in Medicine and Biology, 2016, 42, 624-630.	1.5	10
44	Physico-chemical characterizations of Cr doped persistent luminescence nanoparticles. Proceedings of SPIE, 2016, , .	0.8	2
45	Inhibition of the myostatin/Smad signaling pathway by short decorin-derived peptides. Experimental Cell Research, 2016, 341, 187-195.	2.6	26
46	Long term in vivo imaging with Cr3+ doped spinel nanoparticles exhibiting persistent luminescence. Journal of Luminescence, 2016, 170, 879-887.	3.1	120
47	Metabolism of Flavone-8-acetic Acid in Mice. Anticancer Research, 2016, 36, 3889-98.	1.1	1
48	Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs. Journal of Controlled Release, 2015, 209, 198-206.	9.9	22
49	Design, Properties, and In Vivo Behavior of SuperÂparamagnetic Persistent Luminescence Nanohybrids. Small, 2015, 11, 2696-2704.	10.0	49
50	Enhancement of siRNA lipid-based vector stability and siRNA integrity in human serum with addition of anionic polymer adjuvant. Journal of Drug Delivery Science and Technology, 2015, 26, 1-9.	3.0	10
51	Gadoliniumâ€Đoped Persistent Nanophosphors as Versatile Tool for Multimodal In Vivo Imaging. Advanced Functional Materials, 2015, 25, 331-338.	14.9	98
52	SMAD3 and SP1/SP3 Transcription Factors Collaborate to Regulate Connective Tissue Growth Factor Gene Expression in Myoblasts in Response to Transforming Growth Factor β. Journal of Cellular Biochemistry, 2015, 116, 1880-1887.	2.6	22
53	Preparation and Evaluation of Multiple Nanoemulsions Containing Gadolinium (III) Chelate as a Potential Magnetic Resonance Imaging (MRI) Contrast Agent. Pharmaceutical Research, 2015, 32, 2983-2994.	3.5	13
54	Persistent luminescence in nanophosphors for long term <i>in-vivo</i> bio-imaging. Proceedings of SPIE, 2015, , .	0.8	1

#	Article	IF	CITATIONS
55	Controlling aminosilane layer thickness to extend the plasma half-life of stealth persistent luminescence nanoparticles in vivo. Journal of Materials Chemistry B, 2015, 3, 4009-4016.	5.8	27
56	Poloxamer bioadhesive hydrogel for buccal drug delivery: Cytotoxicity and trans-epithelial permeability evaluations using TR146 human buccal epithelial cell line. International Journal of Pharmaceutics, 2015, 495, 1028-1037.	5.2	26
57	Persistent Luminescence Cr <sup>3+</sup> Doped Spinels and Use as Biomarker for <i>In Vivo</i> Imaging. Advances in Science and Technology, 2014, 90, 157-165.	0.2	1
58	Optical properties and storage capabilities in AB <sub>2</sub> O <sub>4</sub> :Cr <sup>3+</sup> (A=Zn,) Tj ETQq	0 0 0 rgB1 0.8	]Overlock 1
59	Persistent luminescence in ZnGa <sub>2</sub> O <sub>4</sub> :Cr: an outstanding biomarker for <i>in-vivo</i> imaging. Proceedings of SPIE, 2014, , .	0.8	2
60	Storage of Visible Light for Long-Lasting Phosphorescence in Chromium-Doped Zinc Gallate. Chemistry of Materials, 2014, 26, 1365-1373.	6.7	324
61	The in vivo activation of persistent nanophosphors for optical imaging of vascularization, tumours and grafted cells. Nature Materials, 2014, 13, 418-426.	27.5	855
62	Cationic lipid nanocarriers activate Toll-like receptor 2 and NLRP3 inflammasome pathways. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 775-782.	3.3	79
63	Lipidic spherulites as magnetic resonance imaging contrast agents. New Journal of Chemistry, 2014, 38, 5190-5197.	2.8	6
64	Mesoporous persistent nanophosphors for in vivo optical bioimaging and drug-delivery. Nanoscale, 2014, 6, 13970-13976.	5.6	76
65	NF-kB related transgene expression in mouse tibial cranial muscle after pDNA injection followed or not by electrotransfer. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 3257-3263.	2.4	2

66	High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector. Gene Therapy, 2014, 21, 1001-1007.	4.5	19
67	Persistent luminescence of AB2O4:Cr3+ (A=Zn, Mg, B=Ga, Al) spinels: New biomarkers for in vivo imaging. Optical Materials, 2014, 36, 1901-1906.	3.6	93
68	2: BASIC DEFINITIONS AND GENERAL PRINCIPLES. ICP Textbooks in Biomolecular Sciences, 2014, , 7-15.	0.1	0
69	Electrochemical DNA-biosensors: Two-electrode setup well adapted for miniaturized devices. Sensors and Actuators B: Chemical, 2013, 182, 510-513.	7.8	15
70	Xyloglucan-Derivatized Films for the Culture of Adherent Cells and Their Thermocontrolled Detachment: A Promising Alternative to Cells Sensitive to Protease Treatment. Biomacromolecules, 2013, 14, 512-519.	5.4	14
71	In vivo imaging with persistent luminescence silicate-based nanoparticles. Optical Materials, 2013, 35, 1852-1858.	3.6	49
72	Synthesis and inÂvitro evaluation of potential anticancer activity of mono- and bis-1,2,3-triazole	5.5	69

Synthesis and inÂvitro evaluation of potential anticancer activity of mono- and bis-1,2,3-triazole derivatives of bis-alkynes. European Journal of Medicinal Chemistry, 2013, 60, 360-364. 72

#	Article	IF	CITATIONS
73	Prevention of rt-PA induced blood–brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice. Experimental Neurology, 2013, 248, 416-428.	4.1	26
74	Infectivity enhancement of different HIV-1-based lentiviral pseudotypes in presence of the cationic amphipathic peptide LAH4-L1. Journal of Virological Methods, 2013, 189, 375-378.	2.1	21
75	Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. International Journal of Pharmaceutics, 2013, 444, 146-154.	5.2	106
76	Reduced in vitro and in vivo toxicity of siRNA-lipoplexes with addition of polyglutamate. Journal of Controlled Release, 2013, 165, 1-8.	9.9	31
77	Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis. Annals of the Rheumatic Diseases, 2013, 72, 1717-1724.	0.9	38
78	Control of the point defects in oxide materials to enhance functionalities in imaging. Proceedings of SPIE, 2013, , .	0.8	2
79	DNA electroporation in rabbits as a method for generation of high-titer neutralizingÂantisera. Human Vaccines and Immunotherapeutics, 2013, 9, 2147-2156.	3.3	4
80	Evaluation of Nonradiative Clinical Imaging Techniques for the Longitudinal Assessment of Tumour Growth in Murine CT26 Colon Carcinoma. International Journal of Molecular Imaging, 2013, 2013, 1-13.	1.3	19
81	Formulation and cytotoxicity evaluation of new self-emulsifying multiple W/O/W nanoemulsions. International Journal of Nanomedicine, 2013, 8, 611.	6.7	29
82	In vivo optical imaging with rare earth doped Ca_2Si_5N_8 persistent luminescence nanoparticles. Optical Materials Express, 2012, 2, 261.	3.0	126
83	AON-mediated Exon Skipping Restores Ciliation in Fibroblasts Harboring the Common Leber Congenital Amaurosis CEP290 Mutation. Molecular Therapy - Nucleic Acids, 2012, 1, e29.	5.1	94
84	Persistent Luminescence Nanoparticles for Bioimaging. Advances in Intelligent and Soft Computing, 2012, , 37-53.	0.2	4
85	Trap depth optimization to improve optical properties of diopside-based nanophosphors for medical imaging. Proceedings of SPIE, 2012, , .	0.8	11
86	Vascular density and endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours. Tumor Biology, 2012, 33, 1709-1717.	1.8	29
87	Colon Tumor Growth and Antivascular Treatment in Mice: Complementary Assessment with MR Elastography and Diffusion-weighted MR Imaging. Radiology, 2012, 264, 436-444.	7.3	55
88	In Vitro Targeting of Avidin-Expressing Glioma Cells with Biotinylated Persistent Luminescence Nanoparticles. Bioconjugate Chemistry, 2012, 23, 472-478.	3.6	76
89	Identification of Id1-DBL2X of VAR2CSA as a key domain inducing highly inhibitory and cross-reactive antibodies. Vaccine, 2012, 30, 1343-1348.	3.8	31
90	Control of pH responsive peptide self-association during endocytosis is required for effective gene transfer. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 1332-1341.	2.6	21

#	Article	IF	CITATIONS
91	CHAPTER 23. Use of Isoflavones in Inherited Metabolic Diseases: A Focus on Mucopolysaccharidoses. Food and Nutritional Components in Focus, 2012, , 381-398.	0.1	0
92	Electroporation-mediated genetic vaccination for antigen mapping: Application to Plasmodium falciparum VAR2CSA protein. Bioelectrochemistry, 2012, 87, 132-137.	4.6	3
93	A novel thiazolidine compound induces caspase-9 dependent apoptosis in cancer cells. Bioorganic and Medicinal Chemistry, 2012, 20, 5094-5102.	3.0	36
94	InÂvitro and inÂvivo biological evaluation of new 4,5-disubstituted 1,2,3-triazoles as cis-constrained analogs of combretastatin A4. European Journal of Medicinal Chemistry, 2012, 54, 22-32.	5.5	36
95	Identification of decorin derived peptides with a zinc dependent anti-myostatin activity. Neuromuscular Disorders, 2012, 22, 1057-1068.	0.6	16
96	Persistent Luminescence Nanoparticles for Diagnostics and Imaging. ACS Symposium Series, 2012, , 1-25.	0.5	16
97	Investigating relationship between transfection and permeabilization by the electric field and/or the Pluronic® L64 <i>in vitro</i> and <i>in vivo</i> . Journal of Gene Medicine, 2012, 14, 204-215.	2.8	3
98	Functionalized singleâ€walled carbon nanotubes containing traces of iron as new negative MRI contrast agents for <i>in vivo</i> imaging. Contrast Media and Molecular Imaging, 2012, 7, 153-159.	0.8	35
99	Development of a liposomal formulation of the natural flavonoid fisetin. International Journal of Pharmaceutics, 2012, 423, 69-76.	5.2	83
100	Synthesis and functionalization of persistent luminescence nanoparticles with small molecules and evaluation of their targeting ability. International Journal of Pharmaceutics, 2012, 423, 102-107.	5.2	39
101	Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice. International Journal of Pharmaceutics, 2012, 427, 452-459.	5.2	163
102	Smart DNA Vectors Based on Cyclodextrin Polymers: Compaction and Endosomal Release. Pharmaceutical Research, 2012, 29, 384-396.	3.5	6
103	Synthesis and biological evaluation of novel ferrocenyl curcuminoid derivatives. MedChemComm, 2011, 2, 190.	3.4	36
104	Controlling Electron Trap Depth To Enhance Optical Properties of Persistent Luminescence Nanoparticles for In Vivo Imaging. Journal of the American Chemical Society, 2011, 133, 11810-11815.	13.7	348
105	New Generation of Plasmid Backbones Devoid of Antibiotic Resistance Marker for Gene Therapy Trials. Molecular Therapy, 2011, 19, 1942-1949.	8.2	88
106	Protonation of Lipids Impacts the Supramolecular and Biological Properties of Their Self-Assembly. Langmuir, 2011, 27, 12336-12345.	3.5	8
107	Genetic Immunization with Plasmid DNA Mediated by Electrotransfer. Human Gene Therapy, 2011, 22, 789-798.	2.7	21
108	Effect of Core Diameter, Surface Coating, and PEC Chain Length on the Biodistribution of Persistent Luminescence Nanoparticles in Mice. ACS Nano, 2011, 5, 854-862.	14.6	250

7

#	Article	IF	CITATIONS
109	Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: The positive effect of long-term aspirin treatment. Molecular Genetics and Metabolism, 2011, 103, 18-25.	1.1	81
110	Lipothioureas as Lipids for Gene Transfection: A Review. Pharmaceuticals, 2011, 4, 1381-1399.	3.8	8
111	Pre-treatment of cells with pluronic L64 increases DNA transfection mediated by electrotransfer. Journal of Controlled Release, 2011, 149, 117-125.	9.9	13
112	Cell microcarriers and microcapsules of stimuli-responsive polymers. Journal of Controlled Release, 2011, 149, 209-224.	9.9	107
113	A comprehensive study in triblock copolymer membrane interaction. Journal of Controlled Release, 2011, 151, 57-64.	9.9	29
114	Anionic polymers for decreased toxicity and enhanced in vivo delivery of siRNA complexed with cationic liposomes. Journal of Controlled Release, 2011, 152, 393-401.	9.9	67
115	Fisetin disposition and metabolism in mice: Identification of geraldol as an active metabolite. Biochemical Pharmacology, 2011, 82, 1731-1739.	4.4	79
116	Altered HepG2 cell models using etomoxir versus tert-butylhydroperoxide. Cell Biology and Toxicology, 2011, 27, 363-370.	5.3	1
117	Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice. Cancer Chemotherapy and Pharmacology, 2011, 68, 445-455.	2.3	87
118	Domino approach to 2-aroyltrimethoxyindoles as novel heterocyclic combretastatin A4 analogues. European Journal of Medicinal Chemistry, 2011, 46, 95-100.	5.5	23
119	Synthesis of Poly(propylene glycol)â€ <i>block</i> â€Polyethylenimine Triblock Copolymers for the Delivery of Nucleic Acids. Macromolecular Bioscience, 2011, 11, 652-661.	4.1	10
120	The Reverse Block Copolymer Pluronic 25R2 Promotes DNA Transfection of Skeletal Muscle. Macromolecular Bioscience, 2011, 11, 590-594.	4.1	12
121	Formulated siRNAs targeting <i>Rankl</i> prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. Journal of Bone and Mineral Research, 2011, 26, 2452-2462.	2.8	34
122	Xâ€ray Photolysis To Release Ligands from Caged Reagents by an Intramolecular Antenna Sensitive to Magnetic Resonance Imaging. Angewandte Chemie - International Edition, 2011, 50, 9708-9711.	13.8	20
123	Cytosolic phospholipase A2α gene silencing in the myeloid lineage alters development of Th1 responses and reduces disease severity in collagen-induced arthritis. Arthritis and Rheumatism, 2011, 63, 681-690.	6.7	25
124	Identification and Induction of Cytochrome P450s Involved in the Metabolism of Flavone-8-Acetic Acid in Mice. Drug Metabolism Letters, 2011, 5, 73-84.	0.8	2
125	The NTS-DBL2X Region of VAR2CSA Induces Cross-Reactive Antibodies That Inhibit Adhesion of Several Plasmodium falciparum Isolates to Chondroitin Sulfate A. Journal of Infectious Diseases, 2011, 204, 1125-1133.	4.0	58
126	Production of Non Viral DNA Vectors. Current Gene Therapy, 2010, 10, 487-507.	2.0	31

#	Article	IF	CITATIONS
127	Relevance of an Academic GMP Pan-European Vector Infra-Structure (PEVI). Current Gene Therapy, 2010, 10, 414-422.	2.0	4
128	In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells. Blood, 2010, 116, 3505-3516.	1.4	57
129	Synthesis and Application of Lactosylated, <sup>99m</sup> Tc Chelating Albumin for Measurement of Liver Function. Bioconjugate Chemistry, 2010, 21, 589-596.	3.6	24
130	Lipopolythiourea/DNA interaction: A biophysical study. Biophysical Chemistry, 2010, 148, 68-73.	2.8	18
131	Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones. Journal of Inherited Metabolic Disease, 2010, 33, 61-67.	3.6	46
132	Design and Evaluation of Histidine-Rich Amphipathic Peptides for siRNA Delivery. Pharmaceutical Research, 2010, 27, 1426-1436.	3.5	87
133	Fasting Increases the <i>In Vivo</i> Gene Delivery of AAV Vectors. Clinical and Translational Science, 2010, 3, 333-336.	3.1	7
134	Incorporation of 2,3â€Ðiaminopropionic Acid into Linear Cationic Amphipathic Peptides Produces pHâ€Sensitive Vectors. ChemBioChem, 2010, 11, 1266-1272.	2.6	36
135	Glucocorticoidâ€induced leucine zipper is an endogenous antiinflammatory mediator in arthritis. Arthritis and Rheumatism, 2010, 62, 2651-2661.	6.7	80
136	Comparative gene transfer between cationic and thiourea lipoplexes. Journal of Gene Medicine, 2010, 12, 45-54.	2.8	24
137	pFARs, Plasmids free of antibiotic resistance markers, display highâ€ŀevel transgene expression in muscle, skin and tumour cells. Journal of Gene Medicine, 2010, 12, 323-332.	2.8	69
138	Cationic and anionic lipoplexes inhibit gene transfection by electroporation <i>in vivo</i> . Journal of Gene Medicine, 2010, 12, 491-500.	2.8	11
139	Thermoresponsive surfaces for cell culture and enzyme-free cell detachment. Progress in Polymer Science, 2010, 35, 1311-1324.	24.7	109
140	The effect of sterilization methods on the thermo-gelation properties of xyloglucan hydrogels. Polymer Degradation and Stability, 2010, 95, 254-259.	5.8	16
141	Synthesis of fluorinated C-mannopeptides as sialyl Lewisx mimics for E- and P-selectin inhibition. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1957-1960.	2.2	19
142	Study on the sol–gel transition of xyloglucan hydrogels. Carbohydrate Polymers, 2010, 80, 555-562.	10.2	52
143	Nucleic acid transfer with hemifluorinated polycationic lipids. Biomaterials, 2010, 31, 4781-4788.	11.4	24
144	Structure–activity relationships of indole compounds derived from combretastatin A4: Synthesis and biological screening of 5-phenylpyrrolo[3,4-a]carbazole-1,3-diones as potential antivascular agents. European Journal of Medicinal Chemistry, 2010, 45, 3726-3739.	5.5	23

#	Article	IF	CITATIONS
145	Soluble TNF-α receptor secretion from healthy or dystrophic mice after AAV6-mediated muscle gene transfer. Gene Therapy, 2010, 17, 1400-1410.	4.5	6
146	Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models. Cancer Gene Therapy, 2010, 17, 387-397.	4.6	29
147	Investigation of DNA Condensing Properties of Amphiphilic Triblock Cationic Polymers by Atomic Force Microscopy. Langmuir, 2010, 26, 17552-17557.	3.5	5
148	Muscle transfection and permeabilization induced by electrotransfer or pluronic® L64Paired study by optical imaging and MRI. Biochimica Et Biophysica Acta - General Subjects, 2010, 1800, 537-543.	2.4	11
149	DNAJB2 Expression in Normal and Diseased Human and Mouse Skeletal Muscle. American Journal of Pathology, 2010, 176, 2901-2910.	3.8	18
150	Synthesis of cytotoxic ferrocenyl flavones via a ferricenium-mediated 1,6-oxidative cyclization. Chemical Communications, 2010, 46, 5145.	4.1	34
151	Acid-Labile Liposome/pDNA Complexes. Methods in Molecular Biology, 2010, 605, 405-423.	0.9	1
152	Anionic pH Sensitive Lipoplexes. Methods in Molecular Biology, 2010, 605, 435-444.	0.9	3
153	Liposome Biodistribution via Europium Complexes. Methods in Molecular Biology, 2010, 606, 509-518.	0.9	1
154	Polymers for Improving the In Vivo Transduction Efficiency of AAV2 Vectors. PLoS ONE, 2010, 5, e15576.	2.5	13
155	Formulation and evaluation of ATP-containing liposomes including lactosylated ASGPr ligand. Journal of Liposome Research, 2009, 19, 287-300.	3.3	8
156	Generation of High-Titer Neutralizing Antibodies against Botulinum Toxins A, B, and E by DNA Electrotransfer. Infection and Immunity, 2009, 77, 2221-2229.	2.2	23
157	In Vivo Electrochemical Detection of Nitroglycerinâ€Đerived Nitric Oxide in Tumorâ€Bearing Mice. Electroanalysis, 2009, 21, 631-634.	2.9	10
158	Evaluation of the muscle gene transfer activity of a series of amphiphilic triblock copolymers. Journal of Gene Medicine, 2009, 11, 1114-1124.	2.8	18
159	Amphiphilic perfluoroalkyl carbohydrates as new tools for liver imaging. International Journal of Pharmaceutics, 2009, 379, 301-308.	5.2	13
160	Functionalization of single- and multi-walled carbon nanotubes with cationic amphiphiles for plasmid DNA complexation and transfection. Nano Research, 2009, 2, 638-647.	10.4	18
161	A comparison of synthetic oligodeoxynucleotides, DNA fragments and AAV-1 for targeted episomal and chromosomal gene repair. BMC Biotechnology, 2009, 9, 35.	3.3	7
162	Real-time monitoring of cell transplantation in mouse dystrophic muscles by a secreted alkaline phosphatase reporter gene. Gene Therapy, 2009, 16, 815-819.	4.5	9

#	Article	IF	CITATIONS
163	Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery. Gene Therapy, 2009, 16, 746-756.	4.5	25
164	Effects of ciliary muscle plasmid electrotransfer of TNF-α soluble receptor variants in experimental uveitis. Gene Therapy, 2009, 16, 862-873.	4.5	27
165	Iminothiol/thiourea tautomeric equilibrium in thiourea lipids impacts DNA compaction by inducing a cationic nucleation for complex assembly. Biophysical Chemistry, 2009, 145, 7-16.	2.8	9
166	How to make siRNA lipoplexes efficient? Add a DNA cargo. Biochimica Et Biophysica Acta - General Subjects, 2009, 1790, 219-230.	2.4	29
167	Skin-specific promoters for genetic immunisation by DNA electroporation. Vaccine, 2009, 27, 4272-4277.	3.8	29
168	Silicates doped with luminescent ions: useful tools for optical imaging applications. , 2009, , .		2
169	Growth Factor Delivery Approaches in Hydrogels. Biomacromolecules, 2009, 10, 9-18.	5.4	235
170	Flavonoid-Induced Morphological Modifications of Endothelial Cells Through Microtubule Stabilization. Nutrition and Cancer, 2009, 61, 310-321.	2.0	63
171	Evaluation of the Performance of Manganese Phthalocyanines as Superoxide Dismutase Mimics. Current Analytical Chemistry, 2009, 5, 330-338.	1.2	7
172	Synthesis and Evaluation of Amphiphilic Poly(tetrahydrofuran-b-ethylene oxide) Copolymers for DNA Delivery into Skeletal Muscle. Pharmaceutical Research, 2008, 25, 2963-2971.	3.5	22
173	Housekeeping while brain's storming Validation of normalizing factors for gene expression studies in a murine model of traumatic brain injury. BMC Molecular Biology, 2008, 9, 62.	3.0	58
174	Careful adjustment of Epo non-viral gene therapy for β-thalassemic anaemia treatment. Genetic Vaccines and Therapy, 2008, 6, 10.	1.5	11
175	Identification of new markers for neurodegeneration process in the mouse model of Sly disease as revealed by expression profiling of selected genes. Journal of Neuroscience Research, 2008, 86, 3285-3294.	2.9	22
176	Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis and Rheumatism, 2008, 58, 2356-2367.	6.7	95
177	A single thiourea group is not enough to get stable thiourea lipoplexes. Bioorganic and Medicinal Chemistry, 2008, 16, 4003-4008.	3.0	6
178	Synthesis and biological evaluation of new disubstituted analogues of 6-methoxy-3-(3′,4′,5′-trimethoxybenzoyl)-1H-indole (BPR0L075), as potential antivascular agents. Bioorganic and Medicinal Chemistry, 2008, 16, 7494-7503.	3.0	33
179	One-step quantification of single-stranded DNA in the presence of RNA using Oligreen in a real-time polymerase chain reaction thermocycler. Analytical Biochemistry, 2008, 372, 116-118.	2.4	45
180	Design, synthesis and evaluation of potent thymidylate synthase X inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3628-3631.	2.2	37

#	Article	IF	CITATIONS
181	Anionic pH-sensitive pegylated lipoplexes to deliver DNA to tumors. International Journal of Pharmaceutics, 2008, 361, 194-201.	5.2	41
182	Vascular endothelial growth factor reduced hypoxia-induced death of human myoblasts and improved their engraftment in mouse muscles. Gene Therapy, 2008, 15, 404-414.	4.5	53
183	Noncovalent Functionalization of Carbon Nanotubes with Amphiphilic Gd <sup>3+</sup> Chelates: Toward Powerful T <sub>1</sub> and T <sub>2</sub> MRI Contrast Agents. Nano Letters, 2008, 8, 232-236.	9.1	156
184	Lipopolythiourea Transfecting Agents: Lysine Thiourea Derivatives. Bioconjugate Chemistry, 2008, 19, 306-314.	3.6	26
185	Development and Characterization of New Cyclodextrin Polymer-Based DNA Delivery Systems. Bioconjugate Chemistry, 2008, 19, 2311-2320.	3.6	33
186	CD36 Deficiency Leads to Choroidal Involution via COX2 Down-Regulation in Rodents. PLoS Medicine, 2008, 5, e39.	8.4	64
187	Inhibiting Myostatin with Follistatin Improves the Success of Myoblast Transplantation in Dystrophic Mice. Cell Transplantation, 2008, 17, 337-350.	2.5	47
188	Nanoparticles for Imaging and Tumor Gene Delivery. Tumori, 2008, 94, 264-270.	1.1	26
189	pFAR plasmids: New Eukaryotic Expression Vectors for Gene Therapy, devoid of Antibiotic Resistance Markers. Nature Precedings, 2008, , .	0.1	3
190	Delivery of DNA into Muscle for Treating Systemic Diseases: Advantages and Challenges. Methods in Molecular Biology, 2008, 423, 199-214.	0.9	23
191	Current Data on ATP-Containing Liposomes and Potential Prospects To Enhance Cellular Energy Status for Hepatic Applications. Critical Reviews in Therapeutic Drug Carrier Systems, 2008, 25, 305-345.	2.2	15
192	Identification of New Flavone-8-Acetic Acid Metabolites Using Mouse Microsomes and Comparison with Human Microsomes. Drug Metabolism and Disposition, 2007, 35, 2023-2034.	3.3	11
193	Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Annals of the Rheumatic Diseases, 2007, 66, 1143-1150.	0.9	49
194	Lipopolythioureas:Â A New Non-Cationic System for Gene Transfer. Bioconjugate Chemistry, 2007, 18, 484-493.	3.6	33
195	In Vivo Electrochemical Detection of Nitric Oxide in Tumor-Bearing Mice. Analytical Chemistry, 2007, 79, 1030-1033.	6.5	44
196	Nanoprobes with near-infrared persistent luminescence for in vivo imaging. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 9266-9271.	7.1	747
197	Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis. Journal of Gene Medicine, 2007, 9, 596-604.	2.8	56
198	Intraâ€articular electrotransfer of plasmid encoding soluble TNF receptor variants in normal and arthritic mice. Journal of Gene Medicine, 2007, 9, 986-993.	2.8	24

#	Article	IF	CITATIONS
199	Amphiphilic polyether branched molecules to increase the circulation time of cationic particles. Bioorganic and Medicinal Chemistry, 2007, 15, 3176-3186.	3.0	8
200	PEGylation of microspheres for therapeutic embolization: Preparation, characterization and biological performance evaluation. Biomaterials, 2007, 28, 1198-1208.	11.4	19
201	Characterization of monohydroxylated derivatives of the anticancer agent flavone-8-acetic acid by liquid chromatography with on-line UV and mass spectrometry. Rapid Communications in Mass Spectrometry, 2007, 21, 3373-3386.	1.5	5
202	Optimisation of intradermal DNA electrotransfer for immunisation. Journal of Controlled Release, 2007, 124, 81-87.	9.9	71
203	Electrotransfection - An Overview. , 2006, , 189-218.		3
204	Design, Synthesis, and Evaluation of Enhanced DNA Binding New Lipopolythioureas. Bioconjugate Chemistry, 2006, 17, 1200-1208.	3.6	29
205	Optical imaging of luminescence for in vivo quantification of gene electrotransfer in mouse muscle and knee. BMC Biotechnology, 2006, 6, 16.	3.3	37
206	Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice. British Journal of Pharmacology, 2006, 149, 23-30.	5.4	82
207	Synthesis and biological evaluation of (3,4,5-trimethoxyphenyl)indol-3-ylmethane derivatives as potential antivascular agents. Bioorganic and Medicinal Chemistry, 2006, 14, 4410-4426.	3.0	33
208	Liposome biodistribution by time resolved fluorimetry of lipophilic europium complexes. European Biophysics Journal, 2006, 35, 155-161.	2.2	17
209	Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor α in experimental arthritis. Arthritis and Rheumatism, 2006, 54, 1867-1877.	6.7	175
210	Widespread lipoplex-mediated gene transfer to vascular endothelial cells and hemangioblasts in the vertebrate embryo. Developmental Dynamics, 2006, 235, 105-114.	1.8	24
211	Comparison of promoter region constructs forin vivo intramuscular expression. Journal of Gene Medicine, 2006, 8, 636-645.	2.8	11
212	A comparative study on intra-articular versus systemic gene electrotransfer in experimental arthritis. Journal of Gene Medicine, 2006, 8, 1027-1036.	2.8	32
213	Electrotransfer into Skeletal Muscle for Protein Expression. Current Gene Therapy, 2006, 6, 561-578.	2.0	69
214	Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNFâ€Î± soluble receptor in uveitis. FASEB Journal, 2006, 20, 389-391.	0.5	59
215	Incorporation of Poly(Ethylene Glycol )Lipid into Lipoplexes. , 2006, , 273-292.		1
216	Synthesis and Advantages of Acid-Labile Formulations for Lipoplexes. , 2006, , 139-163.	_	0

13

#	Article	IF	CITATIONS
217	Anticancer Gene Therapy by in Vivo DNA Electrotransfer of MBD2 Antisense. , 2005, , 218-229.		0
218	Sialyl Lewisx analogs based on a quinic acid scaffold as the fucose mimic. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3224-3228.	2.2	18
219	Positivein vivo heterologous gene regulation by electric pulses delivery with metallothionein I gene promoter. Journal of Gene Medicine, 2005, 7, 1565-1572.	2.8	4
220	In vivo NMR imaging evaluation of efficiency and toxicity of gene electrotransfer in rat muscle. Gene Therapy, 2005, 12, 1434-1443.	4.5	21
221	Electrophoretic Component of Electric Pulses Determines the Efficacy of In Vivo DNA Electrotransfer. Human Gene Therapy, 2005, 16, 1194-1201.	2.7	126
222	Neutral Postgrafted Colloidal Particles for Gene Delivery. Bioconjugate Chemistry, 2005, 16, 608-614.	3.6	45
223	Electrophoretic Component of Electric Pulses Determines the Efficacy of In Vivo DNA Electrotransfer. Human Gene Therapy, 2005, .	2.7	1
224	LPS-induced bronchial hyperreactivity: interference by mIL-10 differs according to site of delivery. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 286, L98-L105.	2.9	17
225	pH-sensitive PEG lipids containing orthoester linkers: new potential tools for nonviral gene delivery. Journal of Controlled Release, 2004, 99, 423-434.	9.9	142
226	Intramuscular plasmid DNA electrotransfer. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2004, 1676, 138-148.	2.4	85
227	Delivery of electric pulses for DNA electrotransfer to mouse muscle does not induce the expression of stress related genes. Cell Biology and Toxicology, 2004, 20, 25-31.	5.3	18
228	Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation. Genetic Vaccines and Therapy, 2004, 2, 2.	1.5	35
229	Plasmid DNA electrotransfer for intracellular and secreted proteins expression: new methodological developments and applications. Journal of Gene Medicine, 2004, 6, S11-S23.	2.8	119
230	Physicochemical optimisation of plasmid delivery by cationic lipids. Journal of Gene Medicine, 2004, 6, S24-S35.	2.8	138
231	Gene Therapy of Collagen-Induced Arthritis by Electrotransfer of Human Tumor Necrosis Factor-α Soluble Receptor I Variants. Human Gene Therapy, 2004, 15, 189-201.	2.7	66
232	DNA Complexing Lipopolythiourea. Bioconjugate Chemistry, 2004, 15, 1342-1348.	3.6	18
233	New Synthetic Clycolipids for Targeted Gene Transfer: Synthesis, Formulation in Lipoplexes and Specific Interaction with Lectin. Drug Delivery, 2004, 11, 351-363.	5.7	11
234	A New Triantennary Galactose-Targeted PEGylated Gene Carrier, Characterization of Its Complex with DNA, and Transfection of Hepatoma Cells. Bioconjugate Chemistry, 2004, 15, 754-764.	3.6	37

#	Article	IF	CITATIONS
235	Regulation of Gene Expression Using a Conditional RNA Antisense Strategy. Journal of Genome Science and Technology, 2004, 3, 1-13.	0.0	3
236	NLS bioconjugates for targeting therapeutic genes to the nucleus. Advanced Drug Delivery Reviews, 2003, 55, 295-306.	13.7	156
237	Anionic polyethyleneglycol lipids added to cationic lipoplexes increase their plasmatic circulation time. Journal of Controlled Release, 2003, 88, 429-443.	9.9	69
238	Efficacy of interleukin-10 gene electrotransfer into skeletal muscle in mice with collagen-induced arthritis. Journal of Gene Medicine, 2003, 5, 164-171.	2.8	60
239	Transcriptional activation of the metallothionein I gene by electric pulsesin vivo: basis for the development of a new gene switch system. Journal of Gene Medicine, 2003, 5, 773-783.	2.8	9
240	Enhanced antitumor activity of a combination ofMBD2-antisense electrotransfer gene therapy and bleomycin electrochemotherapy. Journal of Gene Medicine, 2003, 5, 893-899.	2.8	27
241	Coupling of importin beta binding peptide on plasmid DNA: transfection efficiency is increased by modification of lipoplex's physico-chemical properties. BMC Biotechnology, 2003, 3, 14.	3.3	19
242	Non-viral gene transfer of murine spleen cells achieved by in vivo electroporation. Gene Therapy, 2003, 10, 569-579.	4.5	32
243	Design, Synthesis, and Evaluation of Gadolinium Cationic Lipids As Tools for Biodistribution Studies of Gene Delivery Complexes. Bioconjugate Chemistry, 2003, 14, 112-119.	3.6	46
244	DNA Complexes with Reducible Cationic Lipid for Gene Transfer. Methods in Enzymology, 2003, 373, 357-369.	1.0	4
245	Lipid reagents for DNA transfer into mammalian cells. New Comprehensive Biochemistry, 2003, 38, 279-289.	0.1	2
246	Cationic Lipids for Transfection. Current Medicinal Chemistry, 2003, 10, 1263-1277.	2.4	56
247	Optimization of plasmid backbone for gene expression in mammalian cells. New Comprehensive Biochemistry, 2003, 38, 349-357.	0.1	0
248	Mechanisms of in Vivo DNA Electrotransfer: Respective Contributions of Cell Electropermeabilization and DNA Electrophoresis. Molecular Therapy, 2002, 5, 133-140.	8.2	280
249	Plasmid DNA Electrotransfer: A New Non Viral Method for Gene Therapy in Oncology. Technology in Cancer Research and Treatment, 2002, 1, 149-152.	1.9	0
250	Folate-Targeted Gene Transfer in Vivo. Molecular Therapy, 2002, 5, 739-744.	8.2	125
251	Applications of Plasmid Electrotransfer. Technology in Cancer Research and Treatment, 2002, 1, 351-354.	1.9	15
252	OPTIMIZATION OF CATIONIC LIPID MEDIATED GENE TRANSFER: STRUCTURE-FUNCTION, PHYSICO-CHEMICAL, AND CELLULAR STUDIES. Journal of Liposome Research, 2002, 12, 95-106.	3.3	14

#	Article	IF	CITATIONS
253	Interleukin-10 expression after intramuscular DNA electrotransfer: kinetic studies. Biochemical and Biophysical Research Communications, 2002, 299, 29-34.	2.1	20
254	AntisenseMBD2 gene therapy inhibits tumorigenesis. Journal of Gene Medicine, 2002, 4, 381-389.	2.8	57
255	Glycosidation of alkylamino-alkan-1-ol. A simple and convenient synthesis of glycosylated cationic lipids. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1447-1450.	2.2	6
256	Viral and non-viral gene therapy partially prevents experimental cisplatin-induced neuropathy. Gene Therapy, 2002, 9, 1333-1337.	4.5	40
257	In vivo plasmid DNA electrotransfer. Current Opinion in Biotechnology, 2002, 13, 443-447.	6.6	67
258	Sphingosine-based liposome as DNA vector for intramuscular gene delivery. Pharmaceutical Research, 2002, 19, 1144-1149.	3.5	14
259	Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo. Nature Biotechnology, 2001, 19, 40-44.	17.5	98
260	Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse. Vaccine, 2001, 19, 1688-1693.	3.8	70
261	Polymorphism of DNA/Multi-cationic Lipid Complexes Driven by Temperature and Salts. Journal of Physical Chemistry B, 2001, 105, 5291-5297.	2.6	26
262	Reducible cationic lipids for gene transfer. Biochemical Journal, 2001, 356, 747.	3.7	43
263	Reducible cationic lipids for gene transfer. Biochemical Journal, 2001, 356, 747-756.	3.7	70
264	Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo. Blood, 2001, 97, 3776-3782.	1.4	53
265	Characterization of oligonucleotide/lipid interactions in submicron cationic emulsions: influence of the cationic lipid structure and the presence of PEG-lipids. Biophysical Chemistry, 2001, 92, 169-181.	2.8	21
266	Synthesis and transfecting properties of a glycosylated polycationic DNA vector 1. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 419-422.	2.2	12
267	2,2,6,6-Tetramethyl-1-piperidinyl-oxyl/[bis(acetoxy)-iodo]benzene-mediated oxidation: A versatile and convenient route to poly(ethylene glycol) aldehyde or carboxylic acid derivatives. Journal of Polymer Science Part A, 2001, 39, 4022-4024.	2.3	21
268	Critical assessment of the nuclear import of plasmid during cationic lipid-mediated gene transfer. Journal of Gene Medicine, 2001, 3, 179-187.	2.8	126
269	Sterically stabilized BGTC-based lipoplexes: structural features and gene transfection into the mouse airwaysin vivo. Journal of Gene Medicine, 2001, 3, 478-487.	2.8	66
270	Oxygen tension and a pharmacological switch in the regulation of transgene expression for gene therapy. Journal of Gene Medicine, 2001, 3, 498-504.	2.8	37

#	Article	IF	CITATIONS
271	Synthesis of New Cationic Lipids from an Unsaturated Glycoside Scaffold. Organic Letters, 2001, 3, 1893-1896.	4.6	20
272	Electrotransfer of naked DNA in the skeletal muscles of animal models of muscular dystrophies. Gene Therapy, 2001, 8, 1097-1107.	4.5	103
273	Factors influencing the oligonucleotides release from O–W submicron cationic emulsions. Journal of Controlled Release, 2001, 70, 243-255.	9.9	25
274	Improvement of mouse β-thalassemia by electrotransfer of erythropoietin cDNA. Experimental Hematology, 2001, 29, 295-300.	0.4	58
275	Coupling of Nuclear Localization Signals to Plasmid DNA. , 2001, 65, 105-109.		0
276	Vers la thérapie génique non virale. Bulletin De L'Academie Nationale De Medecine, 2001, 185, 1683-1697.	0.0	3
277	Formulations which increase the size of lipoplexes prevent serum-associated inhibition of transfection. Journal of Gene Medicine, 2000, 2, 32-40.	2.8	107
278	Genetic chemistry: Tools for gene therapy coming from unexpected directions. Drug Development Research, 2000, 50, 566-572.	2.9	11
279	Introduction of cyclic guanidines into cationic lipids for non-viral gene delivery. Tetrahedron Letters, 2000, 41, 675-679.	1.4	29
280	Non-electrostatic complexes with DNA: towards novel synthetic gene delivery systems. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 911-914.	2.2	14
281	Synthesis of glycosylated polyethylenimine with reduced toxicity and high transfecting efficiency. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1233-1235.	2.2	26
282	Synthesis and biological properties of new glycosidic cationic lipids for DNA delivery. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1393-1395.	2.2	28
283	Efficient DNA electrotransfer into tumors. Bioelectrochemistry, 2000, 52, 83-90.	4.6	59
284	Antiangiogenic Effect of Interleukin-10 in Ischemia-Induced Angiogenesis in Mice Hindlimb. Circulation Research, 2000, 87, 448-452.	4.5	194
285	High-Level Protein Secretion into Blood Circulation after Electric Pulse-Mediated Gene Transfer into Skeletal Muscle. Molecular Therapy, 2000, 2, 204-210.	8.2	121
286	Importance of association between permeabilization and electrophoretic forces for intramuscular DNA electrotransfer. Biochimica Et Biophysica Acta - General Subjects, 2000, 1474, 353-359.	2.4	188
287	Novel Method for Covalent Fluorescent Labeling of Plasmid DNA That Maintains Structural Integrity of the Plasmid. Bioconjugate Chemistry, 2000, 11, 51-55.	3.6	25
288	Reduction-Sensitive Lipopolyamines as a Novel Nonviral Gene Delivery System for Modulated Release of DNA with Improved Transgene Expression. Journal of Medicinal Chemistry, 2000, 43, 4377-4387.	6.4	120

#	Article	IF	CITATIONS
289	Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer. Gene Therapy, 1999, 6, 209-218.	4.5	142
290	Synthetic DNA-compacting peptides derived from human sequence enhance cationic lipid-mediated gene transfer in vitro and in vivo. Gene Therapy, 1999, 6, 282-292.	4.5	101
291	Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic Acids Research, 1999, 27, 3792-3798.	14.5	226
292	Structural characteristics of supramolecular assemblies formed by guanidinium-cholesterol reagents for gene transfection. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2621-2626.	7.1	106
293	pCOR: a new design of plasmid vectors for nonviral gene therapy. Gene Therapy, 1999, 6, 1482-1488.	4.5	109
294	Intracellular fate and nuclear targeting of plasmid DNA. Cell Biology and Toxicology, 1999, 15, 193-202.	5.3	46
295	Protective Role of Interleukin-10 in Atherosclerosis. Circulation Research, 1999, 85, e17-24.	4.5	631
296	Inhibition of cathepsin D by tripeptides containing statine analogs. Biochemical Pharmacology, 1999, 58, 329-333.	4.4	6
297	Secreted Human Placental Alkaline Phosphatase as a Reporter Gene for in Vivo Gene Transfer. Analytical Biochemistry, 1999, 271, 187-189.	2.4	24
298	Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransfer. Journal of Gene Medicine, 1999, 1, 245-250.	2.8	89
299	Coupling of a targeting peptide to plasmid DNA by covalent triple helix formation. FEBS Letters, 1999, 453, 41-45.	2.8	68
300	Cellular uptake of cationic lipid/DNA complexes by cultured myoblasts and myotubes. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1418, 165-175.	2.6	12
301	Coupling of Nuclear Localization Signals to Plasmid DNA and Specific Interaction of the Conjugates with Importin α. Bioconjugate Chemistry, 1999, 10, 49-55.	3.6	110
302	High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 4262-4267.	7.1	865
303	Optimisation des plasmides et des vecteurs synthétiques pour la thérapie génique Medecine/Sciences, 1999, 15, 669.	0.2	3
304	Cationic lipid-mediated gene transfer: analysis of cellular uptake and nuclear import of plasmid DNA. Cell Biology and Toxicology, 1998, 14, 95-104.	5.3	68
305	Application of lipids and plasmid design for gene delivery to mammalian cells. Current Opinion in Biotechnology, 1998, 9, 480-485.	6.6	38
306	Novel non-viral vectors for gene delivery: Synthesis of a second-generation library of mono-functionalized poly-(guanidinium)amines and their introduction into cationic lipids. Biotechnology and Bioengineering, 1998, 61, 81-87.	3.3	25

#	Article	IF	CITATIONS
307	Production of a new DNA vehicle for gene transfer using site-specific recombination. Applied Microbiology and Biotechnology, 1998, 49, 560-567.	3.6	34
308	Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle. Comptes Rendus De L'AcadA©mie Des Sciences SA©rie 3, Sciences De La Vie, 1998, 321, 893-899.	0.8	157
309	Cationic lipid-mediated gene transfer: effect of serum on cellular uptake and intracellular fate of lipopolyamine/DNA complexes. Biochimica Et Biophysica Acta - Biomembranes, 1998, 1368, 276-288.	2.6	178
310	Novel cationic lipids for gene delivery and gene therapy. Expert Opinion on Therapeutic Patents, 1998, 8, 1125-1141.	5.0	16
311	Synthesis, Activity, and Structureâ^'Activity Relationship Studies of Novel Cationic Lipids for DNA Transfer. Journal of Medicinal Chemistry, 1998, 41, 224-235.	6.4	254
312	Virus-sized self-assembling lamellar complexes between plasmid DNA and cationic micelles promote gene transfer. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 14412-14417.	7.1	145
313	Efficient purification of plasmid DNA for gene transfer using triple-helix affinity chromatography. Gene Therapy, 1997, 4, 323-330.	4.5	125
314	A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Therapy, 1997, 4, 1341-1349.	4.5	214
315	Novel nonviral vectors for gene delivery: Synthesis and applications. International Journal of Peptide Research and Therapeutics, 1997, 4, 263-267.	0.1	1
316	Novel nonviral vectors for gene delivery: Synthesis and applications. International Journal of Peptide Research and Therapeutics, 1997, 4, 263-267.	0.1	4
317	Synthesis and conformational analysis of peptide inhibitors of farnesyltransferase. Bioorganic and Medicinal Chemistry, 1997, 5, 115-124.	3.0	16
318	One pot synthesis of unsymmetrically functionalized polyamines by a solid phase strategy starting from their symmetrical polyamine-counterparts. Tetrahedron Letters, 1997, 38, 3219-3222.	1.4	32
319	Triple Helix Formation on Plasmid DNA Determined by a Size-Exclusion Chromatographic Method. Analytical Biochemistry, 1997, 248, 102-110.	2.4	5
320	Synthesis of O-methylsulfonyl derivatives of d-glucose as potential alkylating agents for targeted drug delivery to the brain. Evaluation of their interaction with the human erythrocyte GLUT1 hexose transporter. Carbohydrate Research, 1997, 299, 15-21.	2.3	32
321	Synthesis of glucose-chlorambucil derivatives and their recognition by the human GLUT1 glucose transporter. European Journal of Pharmacology, 1996, 318, 477-484.	3.5	77
322	Hexose keto-C-glycoside conjugates: design, synthesis, cytotoxicity, and evaluation of their affinity for the glucose transporter glut-1. Bioorganic and Medicinal Chemistry, 1996, 4, 2081-2090.	3.0	15
323	Functional Expression of Pâ€Glycoprotein in an Immortalised Cell Line of Rat Brain Endothelial Cells, RBE4. Journal of Neurochemistry, 1996, 67, 988-995.	3.9	96
324	Synthesis of novel ( <i>N</i> â€farnesyl) amino acids and their incorporation into peptides. International Journal of Peptide and Protein Research, 1996, 47, 333-339.	0.1	4

#	Article	IF	CITATIONS
325	Functional Expression of Multidrug Resistance P-Glycoprotein in Cellular Models of Physiological Barriers. Advances in Behavioral Biology, 1996, , 175-183.	0.2	0
326	Gene transfer by naked DNA into adult mouse brain. Gene Therapy, 1996, 3, 405-11.	4.5	60
327	A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 7297-7301.	7.1	5,897
328	Functional expression of the P-glycoproteinmdr in primary cultures of bovine cerebral capillary endothelial cells. Cell Biology and Toxicology, 1995, 11, 283-293.	5.3	14
329	Local constrained shifty pseudopeptides inhibitors of rasfarnesyl transferase. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 2677-2682.	2.2	13
330	Erratum to â€~interaction of pristinamycin IA with P-glycoprotein in human intestinal epithelial cells' [Eur. J. Pharmacol Mol. Pharmacol. (1995) 187–192]. European Journal of Pharmacology, 1995, 289, 479.	2.6	0
331	Interaction of pristinamycin IA with P-glycoprotein in human intestinal epithelial cells. European Journal of Pharmacology, 1995, 288, 187-192.	2.6	27
332	Subcellular distribution of receptor sites in human brain: Differentiation between heavy and light structures of high and low density. Brain Research, 1995, 687, 155-166.	2.2	6
333	Dopamine denervation, age of onset, and Parkinson's disease. Neurology, 1995, 45, 392-392.	1.1	9
334	Induction of Blood-Brain Barrier Differentiation in a Rat Brain-Derived Endothelial Cell Line. Experimental Cell Research, 1995, 220, 161-170.	2.6	54
335	Lipospermine-Based Gene Transfer into the Newborn Mouse Brain Is Optimized by a Low Lipospermine/DNA Charge Ratio. Human Gene Therapy, 1995, 6, 1515-1524.	2.7	87
336	Differentiated intestinal epithelial cell lines asin vitro models for predicting the intestinal absorption of drugs. Cell Biology and Toxicology, 1994, 10, 393-397.	5.3	35
337	Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography. Brain Research, 1994, 659, 1-9.	2.2	33
338	The Catecholamine Transporter of Adrenal Medulla Chromaffin Granules. Annals of the New York Academy of Sciences, 1994, 733, 185-192.	3.8	11
339	Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochemical Pharmacology, 1994, 48, 1528-1530.	4.4	124
340	Autoradiographic Distribution of the Eye Monoaminergic Synaptic Vesicles. Ophthalmic Research, 1994, 26, 232-239.	1.9	0
341	High lipophilicity decreases drug transport across intestinal epithelial cells. Journal of Pharmacology and Experimental Therapeutics, 1994, 269, 654-8.	2.5	94
342	Axonal Transport of Dopamine-containing Vesicles LabelledIn Vivowith [3H] Reserpine. European Journal of Neuroscience, 1993, 5, 449-453.	2.6	10

#	Article	IF	CITATIONS
343	HT29-18-C1 intestinal cells: A new model for studying the epithelial transport of drugs. Biochimica Et Biophysica Acta - Molecular Cell Research, 1993, 1177, 134-138.	4.1	13
344	Dopamine transport: pharmacological distinction between the synaptic membrane and the vesicular transporter in rat striatum. European Journal of Pharmacology, 1992, 218, 175-177.	3.5	18
345	Regulation of the Chromaffin Granule Catecholamine Transporter in Cultured Bovine Adrenal Medullary Cells: Stimulus–Biosynthesis Coupling. Journal of Neurochemistry, 1992, 59, 2105-2112.	3.9	35
346	Synaptin/synaptophysin, p65 and SV2: their presence in adrenal chromaffin granules and sympathetic large dense core vesicles. Biochimica Et Biophysica Acta - Bioenergetics, 1991, 1060, 251-256.	1.0	47
347	Ketanserin as a Ligand of the Vesicular Monoamine Transporter. , 1991, , 147-150.		1
348	Dynamic Properties of Monoamine Storage Vesicles: Pharmacological and Physiological Implications. , 1991, , 193-196.		0
349	Chapter 3 Exogeneous expression of L-dopa and dopamine in various cell lines following transfer of rat and human tyrosine hydroxylase cDNA: grafting in an animal model of Parkinson's disease. Progress in Brain Research, 1990, 82, 23-32.	1.4	25
350	Axonal Transport of Synaptic Vesicles and Muscarinic Receptors: Effect of Protein Synthesis Inhibitors. Journal of Neurochemistry, 1990, 54, 880-885.	3.9	11
351	Association of the GTP-binding protein Rab3A with bovine adrenal chromaffin granules Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 5692-5696.	7.1	194
352	Sympathetic axons and nerve terminals: The protein composition of small and large dense-core and of a third type of vesicles. Neuroscience, 1990, 37, 819-827.	2.3	39
353	Induction of the vesicular monoamine transporter by elevated potassium concentration in cultures of rat sympathetic neurons. Developmental Brain Research, 1990, 52, 161-166.	1.7	21
354	Postnatal development of the monoamine vesicular transporter in mesencephalic and telencephalic regions of the rat brain: A quantitative autoradiographic study with [3H]dihydrotetrabenazine. Neuroscience Letters, 1990, 117, 1-7.	2.1	14
355	[3H]Dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum. Neuroscience Letters, 1990, 114, 45-50.	2.1	47
356	Regulation of neurotensin-containing neurons in the rat striatum and substantia nigra. Effects of unilateral nigral lesion with 6-hydroxydopamine on neurotensin content and its binding site density. Brain Research, 1990, 510, 203-210.	2.2	41
357	Regulation of neurotensin-containing neurons in the rat striatum. Effects of unilateral striatal lesions with quinolinic acid and ibotenic acid on neurotensin content and its binding site density. Brain Research, 1990, 520, 6-13.	2.2	29
358	Striatal dopamine deficiency in parkinson's disease: Role of aging. Annals of Neurology, 1989, 26, 551-557.	5.3	246
359	Predominant Cytosolic Distribution of Serotonin in Rat Pineal Gland in Contrast to Biogenic Monoamine Localization in Midbrain and Adrenal Gland. Journal of Pineal Research, 1989, 7, 23-29.	7.4	3
360	Quantitative autoradiography of the rat brain vesicular monoamine transporter using the binding of [3H]dihydrotetrabenazine and 7-amino-8-[125I]iodoketanserin. Neuroscience, 1989, 33, 341-349.	2.3	53

#	Article	IF	CITATIONS
361	Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochemical Pharmacology, 1989, 38, 2395-2404.	4.4	160
362	Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. Biochemistry, 1989, 28, 1692-1697.	2.5	84
363	[3H]Dihydrotetrabenazine, a New In Vitro Monoaminergic Probe for Human Brain. Journal of Neurochemistry, 1988, 50, 1131-1136.	3.9	84
364	1-methyl-4-phenylpyridinium is a substrate of the vesicular monoamine uptake system of chromaffin granules. European Journal of Pharmacology, 1988, 146, 359-360.	3.5	15
365	Characteristics of the transport of the quaternary ammonium 1-methyl-4-phenylpyridinium by chromaffin granules. Biochemical Pharmacology, 1988, 37, 4381-4387.	4.4	33
366	D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. Journal of the Neurological Sciences, 1988, 86, 291-306.	0.6	83
367	Time required for transmitter accumulation inside monoaminergic storage vesicles differs in peripheral and in central systems. Neuroscience, 1988, 27, 1029-1035.	2.3	39
368	Molecular pharmacology of niaprazine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1988, 12, 989-1001.	4.8	10
369	Noradrenaline, adrenaline and tyrosine hydroxylase in adrenal medulla from parkinsonian patients Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 1104-1105.	1.9	9
370	Hydrophobicity of the tetrabenazine-binding site of the chromaffin granule monoamine transporter. Molecular Pharmacology, 1988, 33, 72-7.	2.3	18
371	Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. Molecular Pharmacology, 1988, 33, 672-7.	2.3	62
372	Molecular Pharmacology of the Monoamine Transporter of the Chromaffin Granule Membrane. Annals of the New York Academy of Sciences, 1987, 493, 194-206.	3.8	33
373	Rat adrenal medulla: Levels of chromogranins, enkephalins, dopamine β-hydroxylase and of the amine transporter are changed by nervous activity and hypophysectomy. Neuroscience, 1987, 22, 131-139.	2.3	134
374	Characterization of the vesicular monoamine transporter in cultured rat sympathetic neurons: Persistence upon induction of cholinergic phenotypic traits. Developmental Biology, 1987, 119, 68-74.	2.0	17
375	Inactivation of the catecholamine transporter during the preparation of chromaffin granule membrane â€~ghosts'. FEBS Letters, 1987, 222, 215-219.	2.8	11
376	Axonal transport of the synaptic vesicle monoamine carrier identified by [3H]dihydrotetrabenazine binding in rat sciatic nerve. Neuroscience Letters, 1987, 77, 231-236.	2.1	6
377	The acylphosphate present in chromaffin granule membrane preparations is not associated with the proton-pump. Biochimie, 1986, 68, 1303-1309.	2.6	7
378	The regionalization of [3H]dihydrotetrabenazine binding sites in the mouse brain and its relationship to the distribution of monoamines and their metabolites. Brain Research, 1986, 370, 176-181.	2.2	49

#	Article	IF	CITATIONS
379	Dihydrotetrabenazine Binding and Monoamine Uptake in Mouse Brain Regions. Journal of Neurochemistry, 1986, 47, 331-339.	3.9	94
380	Uptake of meta-iodobenzylguanidine by bovine chromaffin granule membranes. Molecular Pharmacology, 1986, 29, 275-80.	2.3	63
381	Dicyclohexylcarbodiimide inhibits the monoamine carrier of bovine chromaffin granule membrane. Biochemistry, 1985, 24, 1239-1244.	2.5	24
382	Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding. Molecular Pharmacology, 1984, 25, 113-22.	2.3	92
383	Solubilization of the catecholamine carrier of chromaffin granule membranes in a form that binds substrates and inhibitors of uptake. Biochemistry, 1983, 22, 2805-2810.	2.5	18
384	Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 584-588.	7.1	124
385	The catecholamine carrier of bovine chromaffin granules. Form of the bound amine. Molecular Pharmacology, 1983, 23, 431-6.	2.3	24
386	Internal pH of isolated newly formed and aged neurohypophysial granules Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 476-479.	7.1	37
387	Acido basic properties of the catecholamine uptake inhibitors tetrabenazine and dihydrotetrabenazine. Biochimie, 1982, 64, 915-921.	2.6	12
388	Existence of an adenosine 5'-triphosphate dependent proton translocase in bovine neurosecretory granule membrane. Biochemistry, 1982, 21, 687-694.	2.5	40
389	lonophore mediated catecholamine release from chromaffin granules. Biochemical Pharmacology, 1981, 30, 3277-3283.	4.4	5
390	pH-Dependence of the ATP-Driven Uptake of Noradrenaline by Bovine Chromaffin-Granule Ghosts. FEBS Journal, 1981, 116, 535-539.	0.2	55
391	Effect of drugs on the ATP-induced and pH-gradient-driven monoamine transport by bovine chromaffin granules. Biochemical Pharmacology, 1980, 29, 1883-1890.	4.4	50
392	Oxonol-v as a probe of chromaffin granule membrane potentials. Biochimica Et Biophysica Acta - Biomembranes, 1980, 599, 150-166.	2.6	69
393	Role of the proton electrochemical gradient in monoamine transport by bovine chromaffin granules. Biochimica Et Biophysica Acta - Biomembranes, 1980, 601, 664-677.	2.6	36
394	Synthesis of ATP by an artificially imposed electrochemical proton gradient in chromaffin granule ghosts. FEBS Letters, 1980, 115, 143-147.	2.8	28
395	Combination of thermal ablation by focused ultrasound, pFAR4-IL-12 transfection and lipidic adjuvant provide a distal immune response. Exploration of Medicine, 0, , 398-413.	1.5	0